Seinäjoki, Finland, 2013-10-28 14:30 CET (GLOBE NEWSWIRE) -- Atria Plc COMPANY ANNOUNCEMENT 28 October 2013 at 3.30 pm The deal between Atria Plc and Saarioinen Oy to move on to FCCA phase II investigations The Finnish Competition and Consumer Authority (FCCA) has decided to commence phase two proceeding in a deal whereaby Atria Plc acquires Saarioinen Oy's slaughtering, meet cutting and meet procurement operations. FCCA has given its decision to commence phase two proceeding today on 28th of October 2013. ATRIA PLC Juha Gröhn CEO DISTRIBUTION Nasdaq OMX Helsinki Ltd Principal media www.atriagroup.com
The deal between Atria Plc and Saarioinen Oy to move on to
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Investigation of Stock Transactions: TASK, VBTX, TURN Insights
Financial Investigations for Shareholders of TASK, VBTX, and TURN Halper Sadeh LLC is actively investigating several companies regarding potential violations of federal securities laws affecting shareholders. The investigations focus on significant transactions involving TaskUs, Veritex Holdings, and 180 Degree Capital Corp. TaskUs, Inc. and Its Acquisition by Blackstone...
Continue ReadingComprehensive Analysis of NVIDIA in the Semiconductor Market
Understanding NVIDIA's Position in the Semiconductor Sector In today's fast-paced business environment, it is crucial for investors and industry followers to conduct in-depth analyses of key companies. This article offers a detailed comparison of NVIDIA (NASDAQ: NVDA) with its main competitors in the Semiconductors & Semiconductor Equipment sector. By looking at important...
Continue Reading
Invivyd Set to Showcase PEMGARDA™ Findings at Upcoming Event
Invivyd Prepares for IDWeek 2024 Presentations Invivyd, Inc. (NASDAQ: IVVD) is an innovative biopharmaceutical company focusing on creating solutions for serious viral infections. As they gear up for their participation in IDWeek 2024, they will be unveiling exciting new data concerning their investigational monoclonal antibody, PEMGARDA™ (pemivibart). The conference is...
Continue Reading
The Rising Stars: Growth Potential of Key Investments
Carnival made waves post-pandemic as it clawed its way back from meme stock purgatory. Traders watched the cruise line stumble but now see flickers of recovery amidst hefty debt burdens that peaked around $35 billion. Sure, they pulled in a whopping $1.7 billion net income in the last quarter, but those profit forecasts? All over the place—talk about a mixed bag. And...
Continue Reading
PharmAla Partners with Logistics Expert for Clinical Trials
PharmAla Forms Strategic Alliance for Enhanced US Distribution PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a dedicated biotechnology company, is excited to share its latest strategic move aimed at improving service delivery in the United States. The company has engaged a trusted third-party logistics partner, specialized...
Continue Reading